TOKYO, Japan — Astellas Pharma Inc. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company’s Supplemental New Drug Application (sNDA) for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) as a combination therapy for the first-line treatment of adult...
Latest News
CLEVELAND, Ohio — A recent study from researchers at University Hospitals (UH) Connor Whole Health and UH Rainbow Babies & Children’s Hospital describes a quality improvement project where pain screening procedures were embedded within an outpatient pediatric sickle cell disease (SCD) clinic. The study examined (1) the feasibility of routine pain...
BELFAST, Northern Ireland – People with rare diseases in Northern Ireland have been sharing their stories through a series of short films. There are more than 7,000 known rare conditions worldwide. It is estimated that more than 110,000 people, or one in 17, are impacted by rare conditions in Northern...
ROCKLAND, Mass. — EMD Serono, the Healthcare business of Merck KGaA in the U.S. and Canada, today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or...
Aurora, Colorado – New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene, a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer....
Melbourne, Australia – In the study led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and published in Science Immunology, the researchers found that CD4+ T cells, traditionally called ‘helper T cells’ for their role in aiding the activation of other immune cells, are remarkably effective in...
Leawood, Kansas – Researchers performed a meta-analysis of randomized trial studies that compared the use of amyloid-reducing monoclonal antibodies (MABs) in patients with Alzheimer dementia at a dose consistent with that used in Phase 3 or FDA approval trials with the use of a placebo. Their purpose was to evaluate...
Montreal, Canada – A common stomach bacteria found in two thirds of the world population may be linked to a higher risk of Alzheimer’s disease, new research suggests. The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, investigated whether a clinically apparent Helicobacter pylori (H. pylori)...
Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As the they describe in “Cell Reports”, this cancer induces changes in the large blood vessels through which immune cells normally migrate to the lymph...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer. This approval...